Neboglamine
Neboglamine ( ) (developmental code names CR-2249, XY-2401), formerly known as nebostinel, is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of…
≈ 1 min read
Neboglamine. encyclopegia.org, snapshot enwiki-001377083189. /a/neboglamine
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Neboglamine ( ) (developmental code names CR-2249, XY-2401), formerly known as nebostinel, is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence. It shows cognition- and memory-enhancing effects in animal models. As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1377083189 under CC BY-SA 4.0; modifications have been made.